BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,027,157 | +985.5% | 59,162 | +1201.7% | 0.01% | +1100.0% |
| Q2 2023 | $371,008 | -95.4% | 4,545 | -95.8% | 0.00% | -96.4% |
| Q1 2023 | $8,007,549 | +68493.0% | 107,933 | -23.4% | 0.03% | -33.3% |
| Q4 2022 | $11,674 | -99.9% | 140,851 | +313.4% | 0.04% | +13.5% |
| Q3 2022 | $9,677,000 | -76.0% | 34,075 | -70.8% | 0.04% | -75.3% |
| Q2 2022 | $40,385,000 | -58.3% | 116,503 | -47.9% | 0.15% | -44.2% |
| Q1 2022 | $96,810,000 | +3902.1% | 223,559 | +4682.0% | 0.27% | +3742.9% |
| Q4 2021 | $2,419,000 | -39.9% | 4,675 | -71.2% | 0.01% | -69.6% |
| Q3 2020 | $4,023,000 | -23.6% | 16,241 | -18.5% | 0.02% | -32.4% |
| Q2 2020 | $5,264,000 | +6.5% | 19,935 | -23.5% | 0.03% | -15.0% |
| Q1 2020 | $4,941,000 | +36.4% | 26,058 | +57.9% | 0.04% | +73.9% |
| Q4 2019 | $3,623,000 | -61.1% | 16,507 | -64.8% | 0.02% | -73.6% |
| Q1 2019 | $9,304,000 | +126.5% | 46,858 | +65.1% | 0.09% | +85.1% |
| Q4 2018 | $4,107,000 | -70.3% | 28,380 | -58.1% | 0.05% | -65.4% |
| Q3 2018 | $13,827,000 | +287.7% | 67,741 | +129.7% | 0.14% | +312.1% |
| Q3 2017 | $3,566,000 | – | 29,497 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |